Cancer Therapy News and Research

RSS

GE Healthcare introduces new CESM technology to aid in breast cancer diagnosis

GE Healthcare, a pioneer in digital mammography, today announced the introduction of an innovative technology to aid in breast cancer diagnosis. GE Healthcare's new SenoBright Contrast Enhanced Spectral Mammography technology reduces ambiguity in mammography results, enabling physicians to detect and diagnose cancer with more confidence - even in the densest part of the breast tissue more rapidly and accurately.

1 Jun 2010

IMRT avoids xerostomia, but effectiveness on controlling cancer unclear

An advanced type of cancer radiation is more successful than traditional radiation in avoiding "dry mouth" when treating head and neck cancers, but it is unknown whether the treatment is better or worse at reducing the size of tumors, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.

31 May 2010

Advances in cancer care help people diagnosed with cancer survive the disease

Ed Gardella, a police officer for 31 years, thought he was pretty tough. But then the 70-year old Worcester, Mass. resident was diagnosed with esophageal cancer. "You never forget that moment, where you were that moment you were told you have cancer," said Gardella. "I never thought I was a particularly brave man, nor did I think I was a coward. I was a police officer, a chief of police, but this disease brings everyone to their knees — no one is tougher than cancer."

29 May 2010

IMRT leads to fewer cases of xerostomia than other types of radiation: AHRQ report

28 May 2010

Children's Hospital of Philadelphia announces availability of proton therapy at Roberts Proton Therapy Center

The Children's Hospital of Philadelphia announces the availability of proton therapy, a precise form of cancer radiation that offers potentially life-changing benefits to children with brain tumors and other solid tumors. The Hospital's Cancer Center has recently begun using proton treatment at the new Roberts Proton Therapy Center, a cutting-edge radiation oncology facility located across the street from Children's Hospital in Penn Medicine's Perelman Center for Advanced Medicine.

28 May 2010

Positron Emission Mammography helps evaluate response to neoadjuvant chemotherapy: Study

In a recent study presented at the American Association of Cancer Research Annual Meeting in Washington, DC, researchers at the University of Texas MD Anderson Cancer Center showed that Positron Emission Mammography (PEM) helps evaluate response to neoadjuvant chemotherapy.

28 May 2010

Concord Medical first-quarter total net revenues increase 36.6% to $11.2 million

Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited financial results for the first quarter ended March 31, 2010.

27 May 2010

Use of bisphosphonates associated with risk of developing BON after dental surgery: Study

People undergoing bisphosphonate therapy to prevent or treat osteoporosis (a thinning of the bones) may be unfamiliar with the drug and possible adverse side effects on oral health, according to a study in the May issue of The Journal of the American Dental Association.

27 May 2010

Blocking the activity of death receptor can stop tumor growth: New research study

Every cell contains machinery for self-destruction, used to induce death when damaged or sick. But according to a new research study, a receptor thought to mediate cell suicide in normal cells may actually be responsible for the unrestrained growth of cancerous tumors.

27 May 2010

New $1.4M study to develop novel computer automation techniques for reducing prep time of IMRT for cancer

Rensselaer Polytechnic Institute Professor Richard Radke is leading a new $1.4 million study to develop novel computer automation techniques that could reduce the prep time of a promising cancer-treatment technology from several hours to a few minutes.

27 May 2010

New book summarizes current state of research on NF-κB

NF-κB is a critical signaling molecule in the immune system that regulates cell survival and cell death, lymphocyte responses, and inflammation. Acting as a transcription factor that can receive several inputs, it coordinates distinct gene expression programs in response to a wide variety of stimuli.

26 May 2010

EMEND indication helps women prevent CINV

More women fighting cancers such as breast, lung, colorectal and ovarian can now help prevent the nausea and vomiting associated with their treatment of moderately emetogenic (vomit-inducing) cancer chemotherapy. Although new treatment entities have been developed in the past 10 years for control of chemically-induced nausea and vomiting, CINV remains a significant problem in the context of current practice.

26 May 2010

CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer

Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center in San Antonio (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced pancreatic cancer. The Principal Investigator is Dr. Monica Mita of the CTRC.

26 May 2010

EIRMC, West Valley Medical Center to continue to serve Humana's Medicare Advantage members

Eastern Idaho Regional Medical Center (EIRMC), a full-service regional medical center in Idaho Falls, and West Valley Medical Center, a community hospital in Caldwell, will continue to provide in-network medical care to all Medicare Advantage members enrolled in plans offered by Humana, under terms of a renewal agreement announced today.

26 May 2010

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced plans to submit a Phase III trial design for DAVANAT to the U.S. Food and Drug Administration during the second half of 2010. The Company has added the talent of Peter G. Traber, M.D., to its FDA approval strategy and trial design team.

24 May 2010

State roundup: Genetic testing on campus, Texas docs in Mass., and more

"A plan by the University of California, Berkeley to voluntarily test the DNA of incoming freshman has come under fire from critics who said the school was pushing an unproven technology on impressionable students. The university has said it will send test kits to 5,500 new students to analyze genes that help control the body's responses to alcohol, dairy products and folic acid" (Wohlsen, 5/21).

24 May 2010

UAB Comprehensive Cancer Center commemorates signing of new act for cancer screening programs

The University of Alabama at Birmingham Comprehensive Cancer Center commemorated the signing of legislation requiring the Alabama Department of Public Health to create breast, cervical and colorectal cancer screening programs designed to save the lives of thousands of Alabamians in an event held May 19.

24 May 2010

New therapies can turn cancer into chronic disease

Two new studies suggest that the prolonged use of cancer drugs helped stunt the progress of the disease, a shift from the scheduled courses of treatment typically delivered to patients, The Wall Street Journal reports.

24 May 2010

New study reveals PTPN2 gene loss causes bone cancer

In patients with leukemia, the formation of white blood cells in the bone marrow is disrupted. This makes leukemia patients particularly susceptible to infections, because properly functioning white blood cells ensure protection against intruders such as viruses and bacteria.

21 May 2010

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Researchers at Columbia University recently analyzed the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines. The results, as reported by lead researcher Dr. Aaron Katz in the online-first publication of Integrative Cancer Therapies, show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time and dose-dependent manner.

20 May 2010

Cancer Therapy News and Research

GE Healthcare introduces new CESM technology to aid in breast cancer diagnosis

IMRT avoids xerostomia, but effectiveness on controlling cancer unclear

Advances in cancer care help people diagnosed with cancer survive the disease

IMRT leads to fewer cases of xerostomia than other types of radiation: AHRQ report

Children's Hospital of Philadelphia announces availability of proton therapy at Roberts Proton Therapy Center

Positron Emission Mammography helps evaluate response to neoadjuvant chemotherapy: Study

Concord Medical first-quarter total net revenues increase 36.6% to $11.2 million

Use of bisphosphonates associated with risk of developing BON after dental surgery: Study

Blocking the activity of death receptor can stop tumor growth: New research study

New $1.4M study to develop novel computer automation techniques for reducing prep time of IMRT for cancer

New book summarizes current state of research on NF-κB

EMEND indication helps women prevent CINV

CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer

EIRMC, West Valley Medical Center to continue to serve Humana's Medicare Advantage members

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA

State roundup: Genetic testing on campus, Texas docs in Mass., and more

UAB Comprehensive Cancer Center commemorates signing of new act for cancer screening programs

New therapies can turn cancer into chronic disease

New study reveals PTPN2 gene loss causes bone cancer

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News